

Supplementary Table 2. Anthropometric, clinical, metabolic, and neurological characteristics of patients with T2DM according to the CAN state

Characteristic	No CAN (n=109)	Early CAN (n=16)	Confirmed CAN (n=15)	P value
Sex, males:females	69:40	12:4	12:3	0.304
Age, yr	65.0 (58.0–69.0)	64.5 (57.0–69.0)	61.0 (53.2–64.5)	0.208
Disease duration, yr	9.0 (5.0–15.0)	16.0 (4.0–26.5)	12.0 (5.2–21.5)	0.312
BMI, kg/m ²	28.7 (25.6–31.5)	29.6 (28.8–33.8)	27.8 (23.5–34.4)	0.174
HbA1c, %	6.7 (6.1–7.3)	7.2 (6.5–7.6)	8.4 (7.0–9.6)	0.002 ^{ab}
HbA1c, mmol/mol	50.0 (44.0–56.0)	55.0 (48.0–59.0)	68.0 (53.0–81.0)	0.002 ^{ab}
Total cholesterol, mg/dL	169.0 (138.2–190.0)	164.0 (132.0–194.0)	188.0 (145.7–220.0)	0.337
LDL cholesterol, mg/dL	89.4 (68.0–113.0)	97.8 (65.2–126.4)	83.5 (61.0–115.3)	0.817
HDL cholesterol, mg/dL	45.0 (37.0–55.0)	37.0 (31.2–49.0)	51.0 (35.0–57.2)	0.278
Triglycerides, mg/dL	107.0 (91.2–150.5) ^d	172.5 (116.0–203.0)	136.0 (88.2–178.7)	0.302 ^b
With retinopathy, % ^e	18/103 (17.5)	5/15 (33.3)	9/14 (64.3)	0.001 ^a
With microalbuminuria, % ^h	14/98 (14.3)	5/13 (23.1)	4/11 (36.4)	0.050
eGFR, mL/min/1.73 m ²	85.9 (69.2–97.5)	85.0 (79.7–103.2)	81.0 (66.4–98.9)	0.408
With chronic kidney disease, % ^h	23/98 (23.5)	5/13 (23.1)	5/11 (41.7)	0.206
Casual systolic BP, mm Hg	132.5±18.8 ^c	142.8±20.7 ^f	126.3±16.6	0.232 ^b
Casual diastolic BP, mm Hg	76.6±10.5	79.2±7.6	75.7±10.5	0.144
With hypertension, %	84 (77.1)	13 (81.2)	10 (66.7)	0.974
With cardiovascular disease, %	23 (21.1)	6 (37.5)	5 (33.3)	0.270
With peripheral vascular disease, % ⁱ	17/107 (15.9)	7/15 (46.7)	5 (33.3)	0.019 ^a
Alcohol consumption, %	24/107 (22.4)	5 (31.2)	1 (6.7)	0.185
Current smokers, %	17 (15.6)	5 (31.2)	4 (26.7)	0.254
Regular physical activity, % ^j	45/107 (42.0)	5 (31.2)	2/14 (17.8)	0.086
CARTs score	0.0 (0–1.0) ^e	3.0 (2.0–4.0)	5.0 (4.0–6.0)	<0.0001 ^{ab}
Expiration:inspiration ratio	1.22 (1.15–1.32) ^d	1.12 (1.10–1.18) ^f	1.07 (1.05–1.09)	<0.0001 ^{ab}
30:15 ratio	1.12 (1.08–1.17) ^d	1.07 (1.02–1.12) ^f	1.03 (1.00–1.04)	<0.0001 ^{ab}
Valsalva ratio	1.46 (1.32–1.62) ^e	1.20 (1.14–1.26)	1.13 (1.11–1.18)	<0.0001 ^{ab}
Orthostatic hypotension, mm Hg	10.0 (5.0–15.0) ^c	16.0 (10.0–21.0)	15.0 (11.2–37.2)	0.001 ^{ab}
With DPN, %	55 (50.4)	13 (81.2)	13 (86.7)	0.002 ^a
MNSI	2.0 (0–4.0) ^c	5.0 (1.2–6.0)	6.0 (3.0–8.0)	0.005 ^{ab}
MDNS	3.0 (2.0–6.0) ^d	7.0 (3.0–9.0)	10.0 (5.0–13.0)	0.002 ^{ab}
VPT hallux, V	20.7 (14.0–31.2) ^d	37.3 (28.8–47.3)	35.0 (24.0–45.2)	0.022 ^{ab}
Warm perception threshold, °C	34.6 (33.1–38.0) ^c	38.6 (34.6–39.3)	41.4 (34.8–45.9)	0.010 ^{ab}
Cold perception threshold, °C	30.5 (28.6–31.5)	29.2 (26.6–31.1)	27.0 (19.8–28.5)	0.002 ^{ab}

Values are presented as median (interquartile range), number (%), or mean ± standard deviation. Analysis of variance (parametric) and Kruskal-Wallis test (non-parametric) as tests of significance for means with *post hoc* Bonferroni correction and Dunn's test and the chi-square test for categorical variables were used.

T2DM, type 2 diabetes mellitus; CAN, cardiovascular autonomic neuropathy; BMI, body mass index; HbA1c, glycosylated hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; BP, blood pressure; CART, cardiovascular autonomic reflex test; DPN, diabetic polyneuropathy; MNSI, Michigan Neuropathy Screening Instrument; MDNS, Michigan Diabetic Neuropathy Score; VPT, vibration perception threshold.

^aSignificant P value; ^bNo CAN vs. confirmed CAN: corrected P; No CAN vs. early CAN: ^ccorrected P<0.05, ^dcorrected P<0.01, ^ecorrected P<0.0001; ^fEarly CAN vs. confirmed CAN: corrected P<0.05; Missing data for ^gno CAN patients (n=6), early CAN (n=1) and confirmed CAN (n=1) patient, ^hno CAN patients (n=11), early CAN (n=3) and confirmed CAN (n=4) patient, ⁱno CAN (n=2) patients and confirmed CAN (n=1) patient, ^jno CAN patients (n=2).